406 related articles for article (PubMed ID: 26916570)
1. Diagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society of Thrombosis and Hemostasis Research (GTH).
Appelmann I; Kreher S; Parmentier S; Wolf HH; Bisping G; Kirschner M; Bergmann F; Schilling K; Brümmendorf TH; Petrides PE; Tiede A; Matzdorff A; Griesshammer M; Riess H; Koschmieder S
Ann Hematol; 2016 Apr; 95(5):707-18. PubMed ID: 26916570
[TBL] [Abstract][Full Text] [Related]
2. Prophylaxis and management of venous thromboembolism in patients with myeloproliferative neoplasms: consensus statement of the Haemostasis Working Party of the German Society of Hematology and Oncology (DGHO), the Austrian Society of Hematology and Oncology (ÖGHO) and Society of Thrombosis and Haemostasis Research (GTH e.V.).
Kreher S; Ochsenreither S; Trappe RU; Pabinger I; Bergmann F; Petrides PE; Koschmieder S; Matzdorff A; Tiede A; Griesshammer M; Riess H; ; ;
Ann Hematol; 2014 Dec; 93(12):1953-63. PubMed ID: 25307456
[TBL] [Abstract][Full Text] [Related]
3. A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms.
Rungjirajittranon T; Owattanapanich W; Ungprasert P; Siritanaratkul N; Ruchutrakool T
BMC Cancer; 2019 Feb; 19(1):184. PubMed ID: 30819138
[TBL] [Abstract][Full Text] [Related]
4. Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry.
Kaifie A; Kirschner M; Wolf D; Maintz C; Hänel M; Gattermann N; Gökkurt E; Platzbecker U; Hollburg W; Göthert JR; Parmentier S; Lang F; Hansen R; Isfort S; Schmitt K; Jost E; Serve H; Ehninger G; Berdel WE; Brümmendorf TH; Koschmieder S;
J Hematol Oncol; 2016 Mar; 9():18. PubMed ID: 26944254
[TBL] [Abstract][Full Text] [Related]
5. Relation of platelet abnormalities to thrombosis and hemorrhage in chronic myeloproliferative disorders.
Wehmeier A; Südhoff T; Meierkord F
Semin Thromb Hemost; 1997; 23(4):391-402. PubMed ID: 9263357
[TBL] [Abstract][Full Text] [Related]
6. Perioperative hemostatic management in the cirrhotic patient: a position paper on behalf of the Liver Intensive Care Group of Europe (LICAGE).
Biancofiore G; Blasi A; De Boer MT; Franchini M; Hartmann M; Lisman T; Liumbruno GM; Porte RJ; Saner F; Senzolo M; Werner MJ
Minerva Anestesiol; 2019 Jul; 85(7):782-798. PubMed ID: 30945514
[TBL] [Abstract][Full Text] [Related]
7. Bleeding complications in BCR-ABL negative myeloproliferative neoplasms: prevalence, type, and risk factors in a single-center cohort.
Kander EM; Raza S; Zhou Z; Gao J; Zakarija A; McMahon BJ; Stein BL
Int J Hematol; 2015 Nov; 102(5):587-93. PubMed ID: 26440973
[TBL] [Abstract][Full Text] [Related]
8. Aspirin in essential thrombocythemia: status quo and quo vadis.
Griesshammer M; Bangerter M; van Vliet HH; Michiels JJ
Semin Thromb Hemost; 1997; 23(4):371-7. PubMed ID: 9263354
[TBL] [Abstract][Full Text] [Related]
9. Risk Factors for and Management of MPN-Associated Bleeding and Thrombosis.
Martin K
Curr Hematol Malig Rep; 2017 Oct; 12(5):389-396. PubMed ID: 28948496
[TBL] [Abstract][Full Text] [Related]
10. Bleeding complications in bcr-abl-negative myeloproliferative neoplasms (MPN): A retrospective single-center study of 829 MPN patients.
Wille K; Huenerbein K; Jagenberg E; Sadjadian P; Becker T; Kolatzki V; Meixner R; Marchi H; Fuchs C; Griesshammer M
Eur J Haematol; 2022 Feb; 108(2):154-162. PubMed ID: 34719056
[TBL] [Abstract][Full Text] [Related]
11. [Perioperative hemostasis management].
Tiede A
Chirurg; 2007 Jan; 78(1):69-79; quiz 80-1. PubMed ID: 17216504
[TBL] [Abstract][Full Text] [Related]
12. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera.
Michiels JJ; Berneman Z; Schroyens W; Finazzi G; Budde U; van Vliet HH
Semin Thromb Hemost; 2006 Sep; 32(6):589-604. PubMed ID: 16977569
[TBL] [Abstract][Full Text] [Related]
13. Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot study.
Chang H; Shih LY; Michelson AD; Dunn P; Frelinger AL; Wang PN; Kuo MC; Lin TL; Wu JH; Tang TC
Acta Haematol; 2013; 130(3):181-7. PubMed ID: 23751441
[TBL] [Abstract][Full Text] [Related]
14. From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms.
Stein BL; Martin K
Blood; 2019 Nov; 134(22):1902-1911. PubMed ID: 31778549
[TBL] [Abstract][Full Text] [Related]
15. Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings.
Michiels JJ; van Vliet HH; Berneman Z; Schroyens W; Gadisseur A
Acta Haematol; 2009; 121(2-3):167-76. PubMed ID: 19506363
[TBL] [Abstract][Full Text] [Related]
16. Cyclical thrombocytosis, acquired von Willebrand syndrome and aggressive non-melanoma skin cancers are common in patients with Philadelphia-negative myeloproliferative neoplasms treated with hydroxyurea.
Verner E; Forsyth C; Grigg A
Leuk Lymphoma; 2014 May; 55(5):1139-43. PubMed ID: 23879199
[TBL] [Abstract][Full Text] [Related]
17. Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders.
Cortes J; Kantarjian H
Cancer; 2004 May; 100(10):2064-78. PubMed ID: 15139047
[TBL] [Abstract][Full Text] [Related]
18. Complications in oral and maxillofacial surgery: management of hemostasis and bleeding disorders in surgical procedures.
Malmquist JP
Oral Maxillofac Surg Clin North Am; 2011 Aug; 23(3):387-94. PubMed ID: 21658969
[TBL] [Abstract][Full Text] [Related]
19. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
20. Health care setting and severity, symptom burden, and complications in patients with Philadelphia-negative myeloproliferative neoplasms (MPN): a comparison between university hospitals, community hospitals, and office-based physicians.
Kaifie A; Isfort S; Gattermann N; Hollburg W; Klausmann M; Wolf D; Maintz C; Hänel M; Goekkurt E; Göthert JR; Platzbecker U; Geer T; Parmentier S; Jost E; Serve H; Ehninger G; Berdel WE; Brümmendorf TH; Koschmieder S;
Ann Hematol; 2016 Sep; 95(9):1399-410. PubMed ID: 27334946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
